What we know so far about long-term GLP-1 receptor agonist use is that these therapies, including semaglutide and tirzepatide, have reshaped the weight-loss conversation over the past few years, helping patients achieve results that were difficult to reach through diet and exercise alone.
But as more people settle into extended courses of treatment, two important questions keep surfacing: what happens when you discontinue these medications, and what happens when you stay on them long term? At PHASE Plastic Surgery & Longevity, our board-certified plastic surgeons, Dr. Richard Baxter and Dr. Megan Gray, can answer your questions.
What Does the Current Research Tell Us?
Clinical trials tracking GLP-1 use beyond one year show that patients generally maintain their weight loss as long as they continue the medication. The SELECT cardiovascular outcomes trial followed participants on semaglutide for over three years and found a significant reduction in major cardiac events, suggesting benefits that go beyond the number on the scale (Lincoff et al., 2023). Other research points to a potential longevity benefit from GLP-1 use due to its anti-inflammatory, neuroprotective, and immune-supporting properties.
However, it is also clear that when patients discontinue GLP-1 therapy, a substantial portion of the lost weight tends to return within the first year of discontinuation (Wilding et al., 2022). That rebound effect has prompted many providers, including Dr. Baxter, to have frank conversations with patients regarding what we know and what we don’t know about long-term use. Many patients choose to continue with a micro-dosing regimen for the possible longevity benefits, in addition to helping to maintain the weight loss.
Are There Concerns With Extended Use?
Information available from published trials has shown that the safety profile of GLP-1 use over one to three years is generally favorable, with gastrointestinal side effects, such as nausea and decreased appetite, being the most commonly reported. These tend to lessen as the body adjusts to the medication.
Questions remain about less common risks over longer timescales, including potential effects on the pancreas, thyroid, and lean muscle mass. Loss of muscle mass alongside fat is a documented concern, and Dr. Baxter emphasizes the importance of strength training, adequate protein intake, and possible support with prescription peptides for patients on a GLP-1 protocol to help maintain muscle tissue, which supports metabolism and physical function.
How Does This Fit Into a Broader Health Strategy?
Based on existing knowledge, at PHASE Plastic Surgery & Longevity, we view GLP-1 therapy as a single tool within a larger, individualized plan rather than a continuing standalone solution. For patients who reach their target weight, Dr. Baxter may explore complementary body contouring procedures to address loose skin that remains after significant fat loss, typically prioritizing the abdomen.
Our goal is to develop a strategy that considers your future direction, not just where you are today.
Call Us Today To Discuss What Is Known About Long-Term GLP-1-Based Therapy
What we know so far about long-term GLP-1 use may change as science evolves, and patients need to stay informed.
If you have questions about starting, continuing, or building a plan around GLP-1 receptor agonist therapy, contact us at PHASE Plastic Surgery & Longevity today to schedule a consultation with Dr. Baxter or Dr. Megan Gray.
Sources:
Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
Wilding, J. P. H., et al. (2022). Weight Regain and Cardiometabolic Effects after Withdrawal of Semaglutide. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
